<code id='311BBB8836'></code><style id='311BBB8836'></style>
    • <acronym id='311BBB8836'></acronym>
      <center id='311BBB8836'><center id='311BBB8836'><tfoot id='311BBB8836'></tfoot></center><abbr id='311BBB8836'><dir id='311BBB8836'><tfoot id='311BBB8836'></tfoot><noframes id='311BBB8836'>

    • <optgroup id='311BBB8836'><strike id='311BBB8836'><sup id='311BBB8836'></sup></strike><code id='311BBB8836'></code></optgroup>
        1. <b id='311BBB8836'><label id='311BBB8836'><select id='311BBB8836'><dt id='311BBB8836'><span id='311BBB8836'></span></dt></select></label></b><u id='311BBB8836'></u>
          <i id='311BBB8836'><strike id='311BBB8836'><tt id='311BBB8836'><pre id='311BBB8836'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:leisure time    Page View:31429
          Franklin faces
          Adobe

          Biotech and life sciences investors continue to draw in new funds even as the biotech stock indexes reach new lows.

          On Wednesday, VC firm Bioluminescence Ventures launched with $477 million to invest in biotech startups. The firm was founded by Kouki Harasaki, who was previously a partner at M12, Microsoft’s corporate venture group, and Andreessen Horowitz. He also has a track record at pharmaceutical companies like Novartis and Baxalta.

          advertisement

          Bioluminescence joined at least four other firms — OrbiMed, Sofinnova Partners, Abingworth, and Revelation Partners — in announcing new pools of capital in the last two weeks. Together, they have raised $5.94 billion.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Merck, Johnson & Johnson CEOs will testify on high drug prices
          Merck, Johnson & Johnson CEOs will testify on high drug prices

          Johnson&JohnsonCEOJoaquinDuatoMICHAELBUHOLZER/AFPviaGettyImagesWASHINGTON—MerckCEORobertDavisand

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          Syphilis numbers in the United States reach record heights

          Atissuesamplewiththepresenceofnumerous,corkscrew-shaped,darklystainedTreponemapallidumspirochetes,th